Please assess the completion status of the following clinical trial:

Trial Title: Remission in Subjects With Crohn's Disease, 1 Year Phase

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion:~* Patient must have successfully completed the induction study NCT00055523~* Diagnosis of Crohn's disease~* Willing and able to give informed consent~Exclusion:~* Diagnosis of ulcerative colitis~* Pregnancy or breastfeeding~* Previous use of infliximab or other anti-TNF antagonists~* Previous history of active tuberculosis or listeria infection~* Previous history of cancer other than successfully treated skin cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Double-blind (DB) adalimumab placebo (Type: PLACEBO_COMPARATOR): Double-blind nonactive matching subcutaneous injection
- Double-blind adalimumab 40 mg every other week (eow) (Type: EXPERIMENTAL): Double-blind adalimumab 40 mg eow by subcutaneous injection
- Double-blind adalimumab 40 mg every week (ew) (Type: EXPERIMENTAL): Double-blind adalimumab 40 mg every week by subcutaneous injection
- Open-label adalimumab 40 mg (Type: EXPERIMENTAL): Open-label adalimumab 40 mg eow or ew by subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).